EXHIBIT 99.1 Zoetis Announces Second Quarter 2024 Results • Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Quarter 2024 • Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for Second Quarter 2024 • Reports Adjusted Net Income of $711 Million, or Adjusted Diluted EPS of $1.56, for Second Quarter 2024 • Raises Full Year 2024 Revenue Guidance to ...

Zoetis (ZTS) ended the recent trading session at $182.42, demonstrating a +1.32% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 1.37%. Elsewhere, the Dow lost 1.21%, while the tech-heavy Nasdaq lost 2.3%.Prior to today's trading, shares of the animal health company had gained 2.53% over the past month. This has outpaced the Medical sector's gain of 0.74% and the S&P 500's gain of 1.11% in that time.The investment community will be closely monitorin ...

Wall Street analysts forecast that Zoetis (ZTS) will report quarterly earnings of $1.49 per share in its upcoming release, pointing to a year-over-year increase of 5.7%. It is anticipated that revenues will amount to $2.3 billion, exhibiting an increase of 5.6% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their i ...

The market expects Zoetis (ZTS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Augu ...

The most recent trading session ended with Zoetis (ZTS) standing at $179.84, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 1.11%. Elsewhere, the Dow gained 1.64%, while the tech-heavy Nasdaq added 1.03%.Coming into today, shares of the animal health company had gained 2.44% in the past month. In that same time, the Medical sector lost 0.54%, while the S&P 500 lost 1.16%.The investment community will be closely monitoring th ...

Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "Veterinary Pharmaceutical Manufacturing in Australia - Industry Market Research Report" report has been added to ResearchAndMarkets.com's offering.This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares. Veterinary pharmaceutical manufacturers have endured their ...

Vesnaandjic/E+ via Getty Images Zoetis (NYSE:ZTS) is a leading animal pharmaceutical company, primarily focused on both companion pets and livestock. Zoetis boasts a robust portfolio of long-lasting blockbusters, benefiting from lower R&D costs and quicker development timelines compared to human pharmaceuticals. However, valuation concerns persist amidst reliance on key drug launches for future growth. One-Minute Summary of Zoetis' Business Here are some key highlights of Zoetis' business and industry i ...

Core Insights - Zoetis Inc. is a leading company in the animal healthcare sector, demonstrating strong fundamentals and a significant global presence, with a 10-year total return of nearly 500% [2] - The company has raised its guidance for FY2024, reflecting confidence in its growth drivers, particularly in the Companion Animal segment, which has shown 20% YoY operational growth in Q1 [4] - Despite recent negative media coverage regarding its products, Zoetis maintains that the reported side effects are minimal, with only 1% of 18 million doses administered experiencing issues [4] Company Overview - Zoetis operates with an integrated approach to animal care, focusing on a diverse portfolio that includes both Companion Animal and Livestock segments [3] - The Companion Animal segment is the primary revenue driver, while Livestock remains important but faces challenges due to macroeconomic factors in regions like China and Argentina [3] Financial Performance - Zoetis is projected to achieve an adjusted EBITDA margin of 43.4% in FY2024, slightly below the previous year's 43.6% [6] - The company has a strong profitability grade of "A+" and continues to outperform its peers in the healthcare sector [2][6] Market Sentiment - The stock has shown resilience, recovering from a selloff in April and demonstrating a bullish long-term trend, although it faces resistance around the $200 level [7] - Despite a significant growth premium and some downgrades in estimates, the market appears to be satisfied with Zoetis's reassurances regarding its products [6][7] Product Outlook - Zoetis is optimistic about its products Librela and Solensia, projecting combined peak sales of $1 billion globally, with expectations for significant market share gains outside the US [4] - The CEO emphasized that the majority of users have reported satisfaction with the monoclonal antibodies, suggesting that negative feedback may have been overstated [4]

JHVEPhoto Just over a year ago, I thought Zoetis Inc. (NYSE:ZTS), the undisputed leader in the animal health industry, was fairly valued even at premium valuation multiples given that the company enjoys durable competitive advantages stemming from its scale and brand recognition. Since then, Zoetis stock has gained just 2% while the S&P 500 has soared almost 30%. This underperformance, if continued for longer, may spook investors, but I believe long-term investors should double down on ZTS stock because ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On April 12, 2024, The Wall Street Jou ...